Project Grant R01CA289631
Award Date
9/17/24
Completion Date
8/31/29
Dollars Obligated
$645K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $545,078 to The Johns Hopkins University to conduct research aimed at enhancing the efficacy of radiopharmaceutical therapy for prostate cancer (PC) and renal cell carcinoma (RCC). The research will systematically evaluate the impact of PSMA-based radiopharmaceutical therapy (PSMA-RPT) on glutamine metabolism, a key metabolic pathway in these cancers. The project will assess the effects...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is funding a $602,361 research project at Yale University to develop deep learning-based models for personalized treatment planning of PSMA radiopharmaceutical therapy (RPT) in prostate cancer. The project aims to leverage imaging data from PSMA-PET and SPECT scans to build predictive models that can optimize dosimetry and personalize the dose administered during each cycle of 177Lu-PSMA...
The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging And Dosimetry, LLC, a for-profit limited liability company based in Baltimore, Maryland. The grant, awarded from February 1, 2025 to January 31, 2027, aims to develop a prototype web/cloud-based quantitative SPECT reconstruction software system for clinical trials and dosimetry of emerging radiopharmaceutical cancer therapies,...
The National Cancer Institute (NCI) awarded a $898,497 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Radiopharmaceutical Imaging and Dosimetry, LLC (RAPID) for the development of a cloud-based, customer-responsive dosimetry tool for alpha-particle emitting radiopharmaceutical therapies. The funding will enable RAPID to build upon its previous work and transition from a radiological protection-based dosimetry paradigm to one focused on normal tissue...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $704,563 to the Beckman Research Institute of the City of Hope to develop a quantitative MRI (qMRI) toolset and automated prostate cancer tumor segmentation method. The key products and services to be delivered through this 5-year project include: Building a qMRI toolset using magnetic resonance fingerprinting, arterial spin labeling, and diffusion-weighted MRI to generate...
This Project Grant award in the amount of $538,553 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Miami is funding a longitudinal study to define the role of quantitative multiparametric MRI features and circulating tumor cells as early markers of patient outcomes after radiation therapy and androgen deprivation therapy for intermediate and high-risk prostate cancer patients. The primary early endpoint is freedom from biochemical...
This $399,829 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research at the University of Washington to develop a generalizable framework for personalized re-irradiation of cancer patients. The key objectives are: 1) Describing the evolution of normal tissue damage and recovery after radiation therapy using imaging biomarkers in the liver and lungs, and 2) Exploring the feasibility of personalizing re-irradiation based on the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $571,271 to the University of Texas Health Science Center at Houston to develop a novel PSMA-targeted drug conjugate for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The key objectives are to: (1) synthesize a PSMA-targeted drug conjugate using the microtubule inhibitor cryptophycin as the cytotoxic payload; (2) visualize and quantify the in vivo...
This $509,246 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Regents of the University of Michigan to investigate early drivers of prostate cancer lineage plasticity (LP). The key objectives are to: Determine the mechanisms by which specific transcriptional regulators modulate prostate cancer cell differentiation and hallmarks of cancer. This will provide a detailed understanding of how these regulators block epithelial...
This $589,425 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support the development and validation of machine learning radiogenomic (ML-RGX) models to predict late radiation-induced genitourinary (GU) and gastrointestinal (GI) toxicities in prostate cancer patients. The primary objectives are to: 1) train ML-RGX models for GU and GI toxicity, 2) externally validate the models using data from two large NRG...